Alternatives to ME Therapeutics Holdings

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A global leader in clinical pharmacology and bioanalytical sciences.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

Developing novel immunotherapies and diagnostics for cancer.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A biotechnology company developing genetic therapies for rare disorders.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Developing oral small molecule medicines for immunological and chronic diseases.